Gelteq Ltd
GELS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GELS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GELS
Gelteq Ltd (GELS) is an early-stage drug delivery technology company focused on developing and licensing gel-based formulations for pharmaceutical, nutraceutical, and OTC markets, currently prioritizing a 505(b)(2) pathway for an off-patent API while continuing to incur losses and requiring substantial additional financing.
Key risk: Cash runway risk
Market Cap
$5.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2025.
Gelteq Ltd (GELS) is an early-stage drug delivery technology company focused on developing and licensing gel-based formulations for pharmaceutical, nutraceutical, and OTC markets, currently prioritizing a 505(b)(2) pathway for an off-patent API while continuing to incur losses and requiring substantial additional financing.
- Gelteq is prioritizing a 505(b)(2) regulatory pathway for an off-patent API, with an estimated 12-15 month timeline including lab testing and clinical trials [sec · filed 2025-11-17].
- The company had cash & equivalents of $0.3M as of 2025-06-30 [sec] and reported net losses of AUD$6,645,453 and AUD$3,546,195 for fiscal years ended June 30, 2025 and 2024, respectively [sec · filed 2025-11-17].
- Gelteq's business model focuses on out-licensing its gel delivery technology to partners while continuing to manufacture existing products under license [sec · filed 2025-11-17].
- The company has initiated pre-clinical trials in Melbourne, Australia and India, and has completed dissolution studies for its lead API candidate [sec · filed 2025-11-17].
- Gelteq expects to add animal health, OTC, and pharmaceutical verticals to sales activities by fiscal year 2027, but currently has no approved prescription products and faces significant regulatory and commercialization uncertainties [sec · filed 2025-11-17].
What works
- Gelteq's gel delivery technology is being developed for multiple APIs, including dysphagia-focused candidates, showcasing potential platform versatility [sec · filed 2024-11-15].
- The company has completed dissolution comparisons to existing market products, which may support future bioequivalence studies required for FDA approval [sec · filed 2025-11-17].
- Gelteq has entered into a rental agreement with Monash University for laboratory facilities, indicating ongoing R&D infrastructure [sec · filed 2025-11-17].
What to weigh
- Gelteq is an early-stage company with no approved prescription products and a history of significant net losses, requiring substantial additional financing to continue operations [sec · filed 2025-11-17].
- The company had only $0.3M in cash as of 2025-06-30, raising concerns about its ability to fund planned clinical trials and operations without new capital [sec].
- Gelteq faces a lengthy and expensive clinical development process with uncertain outcomes, and earlier study results may not predict future trial success [sec · filed 2024-11-15].
- The company operates in highly regulated and competitive markets, and there is no assurance that its efforts will result in revenues or profitability [sec · filed 2025-11-17].
From the filings
Quoted directly from source documents.
Gelteq reported significant net losses in recent fiscal years.
“We incurred total losses in the past of approximately AUD$6,645,453 and AUD$3,546,195 in the fiscal years ended June 30, 2025 and 2024 respectively.”
SEC filings · November 17, 2025
Gelteq is pursuing a 505(b)(2) pathway for an off-patent API.
“With one of these off-patent APIs we are entering into the 505(b)(2) pathway, which has the potential to allow us to add a prescription product to our product portfolio that uses our gel base.”
SEC filings · November 15, 2024
Gelteq expects to need substantial additional financing.
“We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.”
SEC filings · November 17, 2025
Risks & what to watch (4)›
Key risks
- Cash runway risk — Only $0.3M cash as of 2025-06-30; may not sustain operations without new financing [sec].
- Clinical and regulatory uncertainty — 505(b)(2) pathway requires costly trials with uncertain outcomes; no approved prescription products yet [sec · filed 2025-11-17].
- History of losses — Net losses of AUD$6.6M and AUD$3.5M in FY2025 and FY2024; profitability not expected soon [sec · filed 2025-11-17].
- Dependence on partnerships — Business model relies on out-licensing; failure to secure partners could harm growth [sec · filed 2025-11-17].
What to watch
- Completion of pre-clinical trials in Melbourne and India, and initiation of human clinical trials for the 505(b)(2) candidate [sec · filed 2025-11-17].
- Ability to secure additional financing or a collaboration agreement to fund ongoing R&D and operations [sec · filed 2025-11-17].
- Progress toward adding animal health, OTC, and pharmaceutical verticals to sales activities by FY2027 [sec · filed 2025-11-17].
- Any updates on FDA interactions or regulatory milestones for the lead gel-based product candidate [sec · filed 2025-11-17].
Sources: SEC filings · Generated August 21, 2026 · How we verify sources →
Run Gelteq Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Gelteq Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$16K
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 13,830 | $9K |
| two sigma investments, lp | 10,052 | $7K |
| wedbush securities inc | 20,000 | $13 |
Short Interest
as of May 21, 2026- % of float
- 0.5%
- Days to cover
- 1.6
- Shares short
- 37,312
- Daily short volume (Jun 10, 2026)
- 34.0%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GELS short interestFrequently asked questions
What is the AI investment thesis for Gelteq Ltd?
Gelteq Ltd (GELS) is an early-stage drug delivery technology company focused on developing and licensing gel-based formulations for pharmaceutical, nutraceutical, and OTC markets, currently prioritizing a 505(b)(2) pathway for an off-patent API while continuing to incur losses and requiring substantial additional financing.
Who is the CEO of Gelteq Ltd?
Mr. Nathan Jacob Givoni is the chief executive officer of Gelteq Ltd (GELS).
Where is Gelteq Ltd headquartered?
Gelteq Ltd (GELS) is headquartered in Clayton, VIC, Australia.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.